| scholarly article | Q13442814 |
| P2093 | author name string | C Koumenis | |
| A Giaccia | |||
| P2860 | cites work | Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen | Q24308837 |
| p53, the cellular gatekeeper for growth and division | Q27860990 | ||
| WAF1, a potential mediator of p53 tumor suppression | Q27861121 | ||
| Animal DNA-dependent RNA polymerases 11. Mechanism of the inhibition of RNA polymerases B by amatoxins | Q28243501 | ||
| P53, cell cycle control and apoptosis: Implications for cancer | Q28611435 | ||
| Induction of apoptosis in fibroblasts by c-myc protein | Q29614346 | ||
| TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB | Q29614706 | ||
| An essential role for NF-kappaB in preventing TNF-alpha-induced cell death | Q29614707 | ||
| p53-dependent apoptosis modulates the cytotoxicity of anticancer agents | Q29615031 | ||
| A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia | Q29615437 | ||
| Participation of p53 protein in the cellular response to DNA damage | Q29618319 | ||
| Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours | Q29618396 | ||
| Suppression of TNF-alpha-induced apoptosis by NF-kappaB | Q29618717 | ||
| Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death | Q29620021 | ||
| Hypoxic Stress Proteins: Survival of the Fittest | Q33862679 | ||
| p53 in signaling checkpoint arrest or apoptosis | Q34395659 | ||
| Characterisation of human cyclin G1 and G2: DNA damage inducible genes | Q34397118 | ||
| Cell type-specific inhibition of p53-mediated apoptosis by mdm2. | Q35847043 | ||
| Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant | Q35853206 | ||
| Drug-induced dispersal of transcribed rRNA genes and transcriptional products: immunolocalization and silver staining of different nucleolar components in rat cells treated with 5,6-dichloro-beta-D-ribofuranosylbenzimidazole | Q36210695 | ||
| Inhibitors of protein synthesis and RNA synthesis prevent neuronal death caused by nerve growth factor deprivation | Q36218697 | ||
| Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage | Q36275074 | ||
| Mechanism of action of dichloro-beta-D-ribofuranosylbenzimidazole: effect on in vitro transcription | Q36295959 | ||
| Localization of an alpha-amanitin resistance mutation in the gene encoding the largest subunit of mouse RNA polymerase II. | Q36483656 | ||
| Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. | Q36665942 | ||
| Fifty years of amanitin | Q36891062 | ||
| Glucocorticoid-induced apoptosis of human leukemic cells is caused by the repressive function of the glucocorticoid receptor | Q37693910 | ||
| A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins | Q38295120 | ||
| Investigations of antisense oligonucleotides targeted against bcl-2 RNAs. | Q38322943 | ||
| Programmed cell death by default in embryonic cells, fibroblasts, and cancer cells | Q40367172 | ||
| Induction of apoptosis by tumor suppressor genes and oncogenes | Q40406124 | ||
| The genetic regulation of apoptosis | Q40525143 | ||
| Death from inside out: an overview | Q40585901 | ||
| Neither macromolecular synthesis nor myc is required for cell death via the mechanism that can be controlled by Bcl-2. | Q40656665 | ||
| Oncogenes and cell death | Q40757516 | ||
| Life, death, and the pursuit of apoptosis. | Q40942974 | ||
| Wild-type p53 negatively regulates the expression of a microtubule-associated protein | Q41148864 | ||
| Alteration of the nucleolar localization of poly(ADP-ribose) polymerase upon treatment with transcription inhibitors | Q41173530 | ||
| Action of dichlorobenzimidazole riboside on RNA synthesis in L-929 and HeLa cells | Q41203044 | ||
| Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis or proliferation in the p53-negative human prostate cancer cell line PC-3. | Q41345327 | ||
| RNA polymerase II C-terminal domain required for enhancer-driven transcription | Q41350631 | ||
| p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes | Q41454039 | ||
| Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. | Q41563742 | ||
| The induction of apoptosis by chemotherapeutic agents occurs in all phases of the cell cycle | Q41625147 | ||
| A central role for chromosome breakage in gene amplification, deletion formation, and amplicon integration | Q41696612 | ||
| Studies on the inhibition by alpha-amanitin of single-step addition reactions and productive RNA synthesis catalysed by wheat-germ RNA polymerase II. | Q42149549 | ||
| A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. | Q45985375 | ||
| Different patterns of apoptosis of HL-60 cells induced by cycloheximide and camptothecin | Q62590591 | ||
| Alteration of the phase and period of a circadian oscillator by a reversible transcription inhibitor | Q67943724 | ||
| Inhibition of RNA polymerase II transcription causes chromatin decondensation, loss of nucleolar structure, and dispersion of chromosomal domains | Q71033983 | ||
| Poly(ADP-ribosyl)ation of histone H1 correlates with internucleosomal DNA fragmentation during apoptosis | Q71058772 | ||
| Blockage of RNA polymerase as a possible trigger for u.v. light-induced apoptosis | Q71408610 | ||
| Inhibitors of transcription such as 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole and isoquinoline sulfonamide derivatives (H-8 and H-7) promote dephosphorylation of the carboxyl-terminal domain of RNA polymerase II largest subunit | Q71622259 | ||
| The transcriptional elongation inhibitor 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole inhibits transcription factor IIH-associated protein kinase | Q71823410 | ||
| U.v.-induced nuclear accumulation of p53 is evoked through DNA damage of actively transcribed genes independent of the cell cycle | Q72185052 | ||
| p53 status and the efficacy of cancer therapy in vivo | Q72839445 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 7306-7316 | |
| P577 | publication date | 1997-12-01 | |
| P1433 | published in | Molecular and Cellular Biology | Q3319478 |
| P1476 | title | Transformed cells require continuous activity of RNA polymerase II to resist oncogene-induced apoptosis | |
| P478 | volume | 17 |
| Q90415585 | Aberrant activation of RPB1 is critical for cell overgrowth in acute myeloid leukemia |
| Q30453623 | Akt-dependent and -independent survival signaling pathways utilized by insulin-like growth factor I. |
| Q35460963 | An in vitro enzymatic assay to measure transcription inhibition by gallium(III) and H3 5,10,15-tris(pentafluorophenyl)corroles |
| Q34857289 | Analogues and derivatives of oncrasin-1, a novel inhibitor of the C-terminal domain of RNA polymerase II and their antitumor activities |
| Q37210876 | Animal toxicity of hairpin pyrrole-imidazole polyamides varies with the turn unit |
| Q37399378 | Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells |
| Q34103117 | Antitumor activity of a novel oncrasin analogue is mediated by JNK activation and STAT3 inhibition |
| Q24628320 | Antitumor activity of a pyrrole-imidazole polyamide |
| Q33952947 | Brain atrophy and neuronal loss in alcoholism: a role for DNA damage? |
| Q39560150 | CDKI-71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol. |
| Q37725409 | Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cells |
| Q24561485 | Cyclin-dependent kinase inhibitor therapy for hematologic malignancies |
| Q36436001 | Effects of 6-thioguanine and S6-methylthioguanine on transcription in vitro and in human cells |
| Q34773140 | Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells |
| Q44948716 | Efficient NES-dependent protein nuclear export requires ongoing synthesis and export of mRNAs. |
| Q37577474 | Implication of transcriptional repression in compound C-induced apoptosis in cancer cells |
| Q43761437 | Induction of ser15 and lys382 modifications of p53 by blockage of transcription elongation. |
| Q78171317 | Inhibition of RNA polymerase II as a trigger for the p53 response |
| Q28345092 | Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis |
| Q37121568 | Interruption of RNA processing machinery by a small compound, 1-[(4-chlorophenyl)methyl]-1H-indole-3-carboxaldehyde (oncrasin-1). |
| Q38949247 | Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016). |
| Q33667315 | Mechanisms of apoptosis by c-Myc |
| Q37542215 | Mitochondrial regulation of cell survival and death during low-oxygen conditions |
| Q28202924 | Modulation of alternative pre-mRNA splicing in vivo by pinin |
| Q40896004 | NF-kappa B is required for H-ras oncogene induced abnormal cell proliferation and tumorigenesis |
| Q37855812 | Novel potent pharmacological cyclin-dependent kinase inhibitors |
| Q42918776 | Nuclear eukaryotic initiation factor 4E (eIF4E) colocalizes with splicing factors in speckles |
| Q44953358 | P53 plays a protective role against UV- and cisplatin-induced apoptosis in transcription-coupled repair proficient fibroblasts. |
| Q54075746 | RNA synthesis block by 5, 6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB) triggers p53-dependent apoptosis in human colon carcinoma cells. |
| Q36120794 | Recent progress in the discovery and development of cyclin-dependent kinase inhibitors |
| Q40006560 | S1-1 nuclear domains: characterization and dynamics as a function of transcriptional activity |
| Q73501415 | Sensitivity to myc-induced apoptosis is retained in spontaneous and transplanted lymphomas of CD2-mycER mice |
| Q34076012 | Strategies for manipulating the p53 pathway in the treatment of human cancer. |
| Q74200551 | Synergistic activation of p53-dependent transcription by two cooperating damage recognition pathways |
| Q46728346 | Synthesis, characterisation, and in vitro evaluation of Pro2-Ile3-S-deoxo-amaninamide and Pro2-D-allo-Ile3-S-deoxo-amaninamide: implications for structure-activity relationships in amanitin conformation and toxicity |
| Q21246017 | The basal transcription machinery as a target for cancer therapy |
| Q39813450 | The cyclin-dependent kinase inhibitor 5, 6-dichloro-1-beta-D-ribofuranosylbenzimidazole induces nongenotoxic, DNA replication-independent apoptosis of normal and leukemic cells, regardless of their p53 status |
| Q42716207 | The multi-kinase inhibitor TG02 overcomes signalling activation by survival factors to deplete MCL1 and XIAP and induce cell death in primary acute myeloid leukaemia cells |
| Q80518102 | Transcription - guarding the genome by sensing DNA damage |
| Q38161381 | Transcription inhibition as a therapeutic target for cancer |
| Q31970093 | UV light-induced degradation of RNA polymerase II is dependent on the Cockayne's syndrome A and B proteins but not p53 or MLH1. |
| Q31126149 | Ultraviolet light-induced apoptosis is associated with S-phase in primary human fibroblasts. |
| Q37788083 | Whether to target single or multiple CDKs for therapy? That is the question |
Search more.